{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:47:05Z","timestamp":1793490425625,"version":"4.5.0"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2023\u201300210923"],"award-info":[{"award-number":["RS-2023\u201300210923"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2025-25397599"],"award-info":[{"award-number":["RS-2025-25397599"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","award":["KSN1722122"],"award-info":[{"award-number":["KSN1722122"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12272-025-01590-w","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:43:19Z","timestamp":1765208599000},"page":"1-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance"],"prefix":"10.1007","volume":"49","author":[{"given":"Heerim","family":"Yeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2915-0742","authenticated-orcid":false,"given":"Sang-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"1590_CR1","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, Ebi H (2020) Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin Cancer Res 26:5962\u20135973. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2077","journal-title":"Clin Cancer Res"},{"key":"1590_CR2","doi-asserted-by":"publisher","first-page":"D679","DOI":"10.1093\/nar\/gkad960","volume":"52","author":"A Agrawal","year":"2024","unstructured":"Agrawal A, Balci H, Hanspers K, Coort SL, Martens M, Slenter DN, Ehrhart F, Digles D, Waagmeester A, Wassink I, Abbassi-Daloii T, Lopes EN, Iyer A, Acosta JM, Willighagen LG, Nishida K, Riutta A, Basaric H, Evelo CT, Willighagen EL, Kutmon M, Pico AR (2024) WikiPathways 2024: next generation pathway database. Nucleic Acids Res 52:D679\u2013D689. https:\/\/doi.org\/10.1093\/nar\/gkad960","journal-title":"Nucleic Acids Res"},{"key":"1590_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/s41467-021-21884-z","volume":"12","author":"AF Aissa","year":"2021","unstructured":"Aissa AF, Islam A, Ariss MM, Go CC, Rader AE, Conrardy RD, Gajda AM, Rubio-Perez C, Valyi-Nagy K, Pasquinelli M, Feldman LE, Green SJ, Lopez-Bigas N, Frolov MV, Benevolenskaya EV (2021) Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat Commun 12:1628. https:\/\/doi.org\/10.1038\/s41467-021-21884-z","journal-title":"Nat Commun"},{"key":"1590_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/CM9.0000000000003247","volume":"137","author":"A Alu","year":"2024","unstructured":"Alu A, Jiang Z, Han X, Cheng Y, Qin F, Ni Y, Zeng H, Li Q, Song Y, Ma X (2024) Ginkgo biloba derivative ginkgetin inhibits breast cancer growth by regulating the miRNA-122-5p\/GALNT10 axis. Chin Med J (Engl) 137:2387\u20132389. https:\/\/doi.org\/10.1097\/CM9.0000000000003247","journal-title":"Chin Med J (Engl)"},{"key":"1590_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/genes16070772","author":"PA Angelopoulos","year":"2025","unstructured":"Angelopoulos PA, Passaro A, Attili I, Trillo Aliaga P, Corvaja C, Spitaleri G, Battaiotto E, Del Signore E, Curigliano G, De Marinis F (2025) Management of MET-driven resistance to osimertinib in EGFR-mutant non-small cell lung cancer. Genes (Basel). https:\/\/doi.org\/10.3390\/genes16070772","journal-title":"Genes (Basel)"},{"key":"1590_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/antiox12071456","volume":"12","author":"U Asma","year":"2023","unstructured":"Asma U, Morozova K, Ferrentino G, Scampicchio M (2023) Apples and apple by-products: antioxidant properties and food applications. Antioxidants 12:1456. https:\/\/doi.org\/10.3390\/antiox12071456","journal-title":"Antioxidants"},{"key":"1590_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences T, Supuran CT","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences T, Supuran CT (2021) Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 20:200\u2013216. https:\/\/doi.org\/10.1038\/s41573-020-00114-z","journal-title":"Nat Rev Drug Discov"},{"key":"1590_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051526","author":"A Aziz","year":"2023","unstructured":"Aziz A, Wang H, Wang Y, Li Z, Yang C, Ma Z, Xiao X, Liu J (2023) Periplocin overcomes bortezomib resistance by suppressing the growth and down-regulation of cell adhesion molecules in multiple myeloma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15051526","journal-title":"Cancers (Basel)"},{"key":"1590_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112748","volume":"148","author":"SJ Baek","year":"2022","unstructured":"Baek SJ, Lee H, Park SM, Park M, Yi JM, Kim NS, Kim A, Cha S (2022) Identification of a novel anticancer mechanism of Paeoniae Radix extracts based on systematic transcriptome analysis. Biomed Pharmacother 148:112748. https:\/\/doi.org\/10.1016\/j.biopha.2022.112748","journal-title":"Biomed Pharmacother"},{"key":"1590_CR10","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.1021\/acs.jmedchem.4c02736","volume":"67","author":"SB Bharate","year":"2024","unstructured":"Bharate SB, Lindsley CW (2024) Natural products driven medicinal chemistry. J Med Chem 67:20723\u201320730. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02736","journal-title":"J Med Chem"},{"key":"1590_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","volume":"11","author":"CM Blakely","year":"2015","unstructured":"Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG (2015) NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep 11:98\u2013110. https:\/\/doi.org\/10.1016\/j.celrep.2015.03.012","journal-title":"Cell Rep"},{"key":"1590_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164168","author":"J Bosch-Barrera","year":"2021","unstructured":"Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyas E, Palmero R, Lopez-Bonet E, Hernandez-Martinez A, Oliveras G, Buxo M, Izquierdo A, Moran T, Nadal E, Menendez JA (2021) Silibinin suppresses tumor cell-intrinsic resistance to nintedanib and enhances its clinical activity in lung cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13164168","journal-title":"Cancers (Basel)"},{"key":"1590_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147946","author":"AB Boz Er","year":"2024","unstructured":"Boz Er AB, Sheldrake HM, Sutherland M (2024) Overcoming vemurafenib resistance in metastatic melanoma: targeting integrins to improve treatment efficacy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25147946","journal-title":"Int J Mol Sci"},{"key":"1590_CR14","doi-asserted-by":"publisher","first-page":"15365","DOI":"10.1038\/s41598-019-51981-5","volume":"9","author":"SM Bray","year":"2019","unstructured":"Bray SM, Lee J, Kim ST, Hur JY, Ebert PJ, Calley JN, Wulur IH, Gopalappa T, Wong SS, Qian HR, Ting JC, Liu J, Willard MD, Novosiadly RD, Park YS, Park JO, Lim HY, Kang WK, Aggarwal A, Kim HC, Reinhard C (2019) Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Sci Rep 9:15365. https:\/\/doi.org\/10.1038\/s41598-019-51981-5","journal-title":"Sci Rep"},{"key":"1590_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq4964","volume":"381","author":"D Bressan","year":"2023","unstructured":"Bressan D, Battistoni G, Hannon GJ (2023) The dawn of spatial omics. Science 381:eabq4964. https:\/\/doi.org\/10.1126\/science.abq4964","journal-title":"Science"},{"key":"1590_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100131","volume":"1","author":"WS Brown","year":"2020","unstructured":"Brown WS, Mcdonald PC, Nemirovsky O, Awrey S, Chafe SC, Schaeffer DF, Li J, Renouf DJ, Stanger BZ, Dedhar S (2020) Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1\/2 complexes in pancreatic cancer. Cell Rep Med 1:100131. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100131","journal-title":"Cell Rep Med"},{"key":"1590_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122259","author":"IM Browne","year":"2024","unstructured":"Browne IM, Okines AFC (2024) Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced oestrogen-receptor-positive breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16122259","journal-title":"Cancers (Basel)"},{"key":"1590_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152900","volume":"59","author":"MR Byun","year":"2019","unstructured":"Byun MR, Lee DH, Jang YP, Lee HS, Choi JW, Lee SK (2019) Repurposing natural products as novel HDAC inhibitors by comparative analysis of gene expression profiles. Phytomedicine 59:152900. https:\/\/doi.org\/10.1016\/j.phymed.2019.152900","journal-title":"Phytomedicine"},{"key":"1590_CR19","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1038\/s41467-019-13058-9","volume":"10","author":"M Caldera","year":"2019","unstructured":"Caldera M, Muller F, Kaltenbrunner I, Licciardello MP, Lardeau CH, Kubicek S, Menche J (2019) Mapping the perturbome network of cellular perturbations. Nat Commun 10:5140. https:\/\/doi.org\/10.1038\/s41467-019-13058-9","journal-title":"Nat Commun"},{"key":"1590_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30030654","author":"L Capasso","year":"2025","unstructured":"Capasso L, De Masi L, Sirignano C, Maresca V, Basile A, Nebbioso A, Rigano D, Bontempo P (2025) Epigallocatechin Gallate (EGCG): pharmacological properties, biological activities and therapeutic potential. Molecules. https:\/\/doi.org\/10.3390\/molecules30030654","journal-title":"Molecules"},{"key":"1590_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/msb.2010.108","volume":"6","author":"E Caron","year":"2010","unstructured":"Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S, Perreault C, Roux PP, Kitano H (2010) A comprehensive map of the mTOR signaling network. Mol Syst Biol 6:453. https:\/\/doi.org\/10.1038\/msb.2010.108","journal-title":"Mol Syst Biol"},{"key":"1590_CR22","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1172\/JCI34739","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065\u20133074. https:\/\/doi.org\/10.1172\/JCI34739","journal-title":"J Clin Invest"},{"key":"1590_CR23","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","volume":"20","author":"AS Castanza","year":"2023","unstructured":"Castanza AS, Recla JM, Eby D, Thorvaldsdottir H, Bult CJ, Mesirov JP (2023) Extending support for mouse data in the molecular signatures database (MSigDB). Nat Methods 20:1619\u20131620. https:\/\/doi.org\/10.1038\/s41592-023-02014-7","journal-title":"Nat Methods"},{"key":"1590_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1080\/01635581.2012.716898","volume":"64","author":"L Castillo-Pichardo","year":"2012","unstructured":"Castillo-Pichardo L, Dharmawardhane SF (2012) Grape polyphenols inhibit Akt\/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr Cancer 64:1058\u20131069. https:\/\/doi.org\/10.1080\/01635581.2012.716898","journal-title":"Nutr Cancer"},{"key":"1590_CR25","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/0008-5472.CAN-12-4619","volume":"73","author":"B Cen","year":"2013","unstructured":"Cen B, Mahajan S, Wang W, Kraft AS (2013) Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res 73:3402\u20133411. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4619","journal-title":"Cancer Res"},{"key":"1590_CR26","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1073\/pnas.1018001108","volume":"109","author":"A Chakrabarty","year":"2012","unstructured":"Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109:2718\u20132723. https:\/\/doi.org\/10.1073\/pnas.1018001108","journal-title":"Proc Natl Acad Sci USA"},{"key":"1590_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58\u201371. https:\/\/doi.org\/10.1016\/j.ccr.2010.10.031","journal-title":"Cancer Cell"},{"key":"1590_CR28","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O\u2019day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, Mcarthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"1590_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cpt.318","volume":"99","author":"B Chen","year":"2016","unstructured":"Chen B, Butte AJ (2016) Leveraging big data to transform target selection and drug discovery. Clin Pharmacol Ther 99:285\u2013297. https:\/\/doi.org\/10.1002\/cpt.318","journal-title":"Clin Pharmacol Ther"},{"key":"1590_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jgr.2021.07.002","volume":"46","author":"YJ Chen","year":"2022","unstructured":"Chen YJ, Wu JY, Deng YY, Wu Y, Wang XQ, Li AS, Wong LY, Fu XQ, Yu ZL, Liang C (2022) Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models. J Ginseng Res 46:418\u2013425. https:\/\/doi.org\/10.1016\/j.jgr.2021.07.002","journal-title":"J Ginseng Res"},{"key":"1590_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101471","volume":"5","author":"M Chen","year":"2024","unstructured":"Chen M, Mainardi S, Lieftink C, Velds A, De Rink I, Yang C, Kuiken HJ, Morris B, Edwards F, Jochems F, Van Tellingen O, Boeije M, Proost N, Jansen RA, Qin S, Jin H, Koen Van Der Mijn JC, Schepers A, Venkatesan S, Qin W, Beijersbergen RL, Wang L, Bernards R (2024a) Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep Med 5:101471. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101471","journal-title":"Cell Rep Med"},{"key":"1590_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107099","volume":"202","author":"T Chen","year":"2024","unstructured":"Chen T, Xiao Z, Liu X, Wang T, Wang Y, Ye F, Su J, Yao X, Xiong L, Yang DH (2024b) Natural products for combating multidrug resistance in cancer. Pharmacol Res 202:107099. https:\/\/doi.org\/10.1016\/j.phrs.2024.107099","journal-title":"Pharmacol Res"},{"key":"1590_CR33","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/jca.109420","volume":"16","author":"X Chen","year":"2025","unstructured":"Chen X, Zheng T, Hao B, Lin S, Yue L, Fan L (2025) Development of traditional Chinese medicine in combination with EGFR inhibitors against cancer. J Cancer 16:2595. https:\/\/doi.org\/10.7150\/jca.109420","journal-title":"J Cancer"},{"key":"1590_CR34","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/tox.23450","volume":"37","author":"YJ Chiu","year":"2022","unstructured":"Chiu YJ, Yang JS, Tsai FJ, Chiu HY, Juan YN, Lo YH, Chiang JH (2022) Curcumin suppresses cell proliferation and triggers apoptosis in vemurafenib-resistant melanoma cells by downregulating the EGFR signaling pathway. Environ Toxicol 37:868\u2013879. https:\/\/doi.org\/10.1002\/tox.23450","journal-title":"Environ Toxicol"},{"key":"1590_CR35","doi-asserted-by":"publisher","first-page":"1328728","DOI":"10.3389\/fonc.2024.1328728","volume":"14","author":"A Chour","year":"2024","unstructured":"Chour A, Toffart AC, Berton E, Duruisseaux M (2024) Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer. Front Oncol 14:1328728. https:\/\/doi.org\/10.3389\/fonc.2024.1328728","journal-title":"Front Oncol"},{"key":"1590_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030653","author":"J Chun","year":"2023","unstructured":"Chun J, Park SM, Lee M, Ha IJ, Jeong MK (2023) The Sesquiterpene lactone-rich fraction of Inula helenium L. enhances the antitumor effect of anti-PD-1 antibody in colorectal cancer: integrative phytochemical, transcriptomic, and experimental analyses. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15030653","journal-title":"Cancers (Basel)"},{"key":"1590_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41375-022-01554-9","volume":"36","author":"K Clesham","year":"2022","unstructured":"Clesham K, Walf-Vorderwulbecke V, Gasparoli L, Virely C, Cantilena S, Tsakaneli A, Inglott S, Adams S, Samarasinghe S, Bartram J, Williams G, De Boer J, Williams O (2022) Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia 36:1541\u20131549. https:\/\/doi.org\/10.1038\/s41375-022-01554-9","journal-title":"Leukemia"},{"key":"1590_CR38","doi-asserted-by":"publisher","first-page":"D138","DOI":"10.1093\/nar\/gkad965","volume":"52","author":"E Clough","year":"2024","unstructured":"Clough E, Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Lee H, Zhang N, Serova N, Wagner L, Zalunin V, Kochergin A, Soboleva A (2024) NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update. Nucleic Acids Res 52:D138\u2013D144. https:\/\/doi.org\/10.1093\/nar\/gkad965","journal-title":"Nucleic Acids Res"},{"key":"1590_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227\u2013235. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0341","journal-title":"Cancer Discov"},{"key":"1590_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13020-025-01124-y","volume":"20","author":"D Cui","year":"2025","unstructured":"Cui D, Zhang C, Zhang L, Zheng J, Wang J, He L, Jin H, Kang Q, Zhang Y, Li N (2025) Natural anticancer products: insights from herbal medicine. Chin Med 20:82. https:\/\/doi.org\/10.1186\/s13020-025-01124-y","journal-title":"Chin Med"},{"key":"1590_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-024-00245-z","volume":"36","author":"K Dave","year":"2024","unstructured":"Dave K, Patel D, Dave N, Jain M (2024) Genomic strategies for drug repurposing. J Egypt Natl Canc Inst 36:35. https:\/\/doi.org\/10.1186\/s43046-024-00245-z","journal-title":"J Egypt Natl Canc Inst"},{"key":"1590_CR42","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","volume":"2","author":"D Ercan","year":"2012","unstructured":"Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Janne PA (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2:934\u2013947. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0103","journal-title":"Cancer Discov"},{"key":"1590_CR43","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/15548627.2016.1271512","volume":"13","author":"N Eritja","year":"2017","unstructured":"Eritja N, Chen BJ, Rodriguez-Barrueco R, Santacana M, Gatius S, Vidal A, Marti MD, Ponce J, Bergada L, Yeramian A, Encinas M, Ribera J, Reventos J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navas D (2017) Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 13:608\u2013624. https:\/\/doi.org\/10.1080\/15548627.2016.1271512","journal-title":"Autophagy"},{"key":"1590_CR44","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20166796","volume":"13","author":"M Fallahi-Sichani","year":"2017","unstructured":"Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, Shah P, Rotem A, Garraway LA, Sorger PK (2017) Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol 13:905. https:\/\/doi.org\/10.15252\/msb.20166796","journal-title":"Mol Syst Biol"},{"key":"1590_CR45","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/bib\/bbx045","volume":"19","author":"J Fang","year":"2018","unstructured":"Fang J, Liu C, Wang Q, Lin P, Cheng F (2018) In silico polypharmacology of natural products. Brief Bioinform 19:1153\u20131171. https:\/\/doi.org\/10.1093\/bib\/bbx045","journal-title":"Brief Bioinform"},{"key":"1590_CR46","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Franca","year":"2024","unstructured":"Franca GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, Rao A, Patel AS, Misirlioglu S, Barkley D, Tang KH, Dolgalev I, Liberman DA, Avital G, Kuperwaser F, Chiodin M, Levine DA, Papagiannakopoulos T, Marusyk A, Lionnet T, Yanai I (2024) Cellular adaptation to cancer therapy along a resistance continuum. Nature 631:876\u2013883. https:\/\/doi.org\/10.1038\/s41586-024-07690-9","journal-title":"Nature"},{"key":"1590_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201796","volume":"13","author":"M Fukuoka","year":"2018","unstructured":"Fukuoka M, Yoshioka K, Hohjoh H (2018) NF-kappaB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells. PLoS ONE 13:e0201796. https:\/\/doi.org\/10.1371\/journal.pone.0201796","journal-title":"PLoS ONE"},{"key":"1590_CR48","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1021\/acs.jmedchem.4c01257","volume":"68","author":"A Gangwal","year":"2025","unstructured":"Gangwal A, Lavecchia A (2025) Artificial intelligence in natural product drug discovery: current applications and future perspectives. J Med Chem 68:3948\u20133969. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01257","journal-title":"J Med Chem"},{"key":"1590_CR49","doi-asserted-by":"publisher","first-page":"D1404","DOI":"10.1093\/nar\/gkae1037","volume":"53","author":"K Gao","year":"2025","unstructured":"Gao K, Liu L, Lei S, Li Z, Huo P, Wang Z, Dong L, Deng W, Bu D, Zeng X, Li C, Zhao Y, Zhang W, Wang W, Wu Y (2025) HERB 2.0: an updated database integrating clinical and experimental evidence for traditional Chinese medicine. Nucleic Acids Res 53:D1404\u2013D1414. https:\/\/doi.org\/10.1093\/nar\/gkae1037","journal-title":"Nucleic Acids Res"},{"key":"1590_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2025.2529458","author":"W Gebrehiwot","year":"2025","unstructured":"Gebrehiwot W, Tok KC, Alkhashi JS, Bakare O, Gumustas M (2025) Emetine: advances in pharmacology, toxicology, and chromatographic approaches. Crit Rev Anal Chem. https:\/\/doi.org\/10.1080\/10408347.2025.2529458","journal-title":"Crit Rev Anal Chem"},{"key":"1590_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/iyad031","author":"C Gene Ontology","year":"2023","unstructured":"Gene Ontology C, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, Feuermann M, Gaudet P, Harris NL, Hill DP, Lee R, Mi H, Moxon S, Mungall CJ, Muruganugan A, Mushayahama T, Sternberg PW, Thomas PD, Van Auken K, Ramsey J, Siegele DA, Chisholm RL, Fey P, Aspromonte MC, Nugnes MV, Quaglia F, Tosatto S, Giglio M, Nadendla S, Antonazzo G, Attrill H, Dos Santos G, Marygold S, Strelets V, Tabone CJ, Thurmond J, Zhou P, Ahmed SH, Asanitthong P, Luna Buitrago D, Erdol MN, Gage MC, Ali Kadhum M, Li KYC, Long M, Michalak A, Pesala A, Pritazahra A, Saverimuttu SCC, Su R, Thurlow KE, Lovering RC, Logie C, Oliferenko S, Blake J, Christie K, Corbani L, Dolan ME, Drabkin HJ, Hill DP, Ni L, Sitnikov D, Smith C, Cuzick A, Seager J, Cooper L, Elser J, Jaiswal P, Gupta P, Jaiswal P, Naithani S, Lera-Ramirez M, Rutherford K, Wood V, De Pons JL, Dwinell MR, Hayman GT, Kaldunski ML, Kwitek AE, Laulederkind SJF, Tutaj MA, Vedi M, Wang SJ, D\u2019eustachio P, Aimo L, Axelsen K, Bridge A, Hyka-Nouspikel N, Morgat A, Aleksander SA, Cherry JM, Engel SR, Karra K, Miyasato SR, Nash RS, Skrzypek MS, Weng S, Wong ED, Bakker E (2023) The gene ontology knowledgebase in 2023. Genetics. https:\/\/doi.org\/10.1093\/genetics\/iyad031","journal-title":"Genetics"},{"key":"1590_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28248141","author":"N Georgiou","year":"2023","unstructured":"Georgiou N, Kakava MG, Routsi EA, Petsas E, Stavridis N, Freris C, Zoupanou N, Moschovou K, Kiriakidi S, Mavromoustakos T (2023) Quercetin: a potential polydynamic drug. Molecules. https:\/\/doi.org\/10.3390\/molecules28248141","journal-title":"Molecules"},{"key":"1590_CR53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cels.2020.10.002","volume":"11","author":"L Gerosa","year":"2020","unstructured":"Gerosa L, Chidley C, Frohlich F, Sanchez G, Lim SK, Muhlich J, Chen JY, Vallabhaneni S, Baker GJ, Schapiro D, Atanasova MI, Chylek LA, Shi T, Yi L, Nicora CD, Claas A, Ng TSC, Kohler RH, Lauffenburger DA, Weissleder R, Miller MA, Qian WJ, Wiley HS, Sorger PK (2020) Receptor-driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells. Cell Syst 11:478-494 e9. https:\/\/doi.org\/10.1016\/j.cels.2020.10.002","journal-title":"Cell Syst"},{"key":"1590_CR54","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00204-024-03786-3","volume":"98","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Das SK, Sinha K, Ghosh B, Sen K, Ghosh N, Sil PC (2024) The emerging role of natural products in cancer treatment. Arch Toxicol 98:2353\u20132391. https:\/\/doi.org\/10.1007\/s00204-024-03786-3","journal-title":"Arch Toxicol"},{"key":"1590_CR55","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.tips.2024.10.003","volume":"45","author":"ZR Goddard","year":"2024","unstructured":"Goddard ZR, Searcey M, Osbourn A (2024) Advances in triterpene drug discovery. Trends Pharmacol Sci 45:964\u2013968. https:\/\/doi.org\/10.1016\/j.tips.2024.10.003","journal-title":"Trends Pharmacol Sci"},{"key":"1590_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/cbdd.14231","volume":"102","author":"A Goel","year":"2023","unstructured":"Goel A (2023) Current understanding and future prospects on Berberine for anticancer therapy. Chem Biol Drug des 102:177\u2013200. https:\/\/doi.org\/10.1111\/cbdd.14231","journal-title":"Chem Biol Drug des"},{"key":"1590_CR57","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1172\/JCI96148","volume":"128","author":"K Gong","year":"2018","unstructured":"Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500\u20132518. https:\/\/doi.org\/10.1172\/JCI96148","journal-title":"J Clin Invest"},{"key":"1590_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15040141","author":"MJ Hadfield","year":"2025","unstructured":"Hadfield MJ, Carneiro BA, Cheng L (2025) Targeted therapeutic approaches for the treatment of cancer: the future is bright. J Pers Med. https:\/\/doi.org\/10.3390\/jpm15040141","journal-title":"J Pers Med"},{"key":"1590_CR59","doi-asserted-by":"publisher","first-page":"1168298","DOI":"10.3389\/fmolb.2023.1168298","volume":"10","author":"A Hafeez","year":"2023","unstructured":"Hafeez A, Khan Z, Armaghan M, Khan K, Sonmez Gurer E, Abdull Razis AF, Modu B, Almarhoon ZM, Setzer WN, Sharifi-Rad J (2023) Exploring the therapeutic and anti-tumor properties of morusin: a review of recent advances. Front Mol Biosci 10:1168298. https:\/\/doi.org\/10.3389\/fmolb.2023.1168298","journal-title":"Front Mol Biosci"},{"key":"1590_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41420-023-01476-0","volume":"9","author":"S Han","year":"2023","unstructured":"Han S, Tian Z, Tian H, Han H, Zhao J, Jiao Y, Wang C, Hao H, Wang S, Fu J, Xue D, Sun H, Li P (2023) HDGF promotes gefitinib resistance by activating the PI3K\/AKT and MEK\/ERK signaling pathways in non-small cell lung cancer. Cell Death Discov 9:181. https:\/\/doi.org\/10.1038\/s41420-023-01476-0","journal-title":"Cell Death Discov"},{"key":"1590_CR61","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1146\/annurev-pharmtox-040323-040828","volume":"64","author":"C Hasselgren","year":"2024","unstructured":"Hasselgren C, Oprea TI (2024) Artificial intelligence for drug discovery: are we there yet? Annu Rev Pharmacol Toxicol 64:527\u2013550. https:\/\/doi.org\/10.1146\/annurev-pharmtox-040323-040828","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1590_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA (2016) Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22:262\u2013269. https:\/\/doi.org\/10.1038\/nm.4040","journal-title":"Nat Med"},{"key":"1590_CR63","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S426685","volume":"17","author":"R He","year":"2023","unstructured":"He R, Jia B, Peng D, Chen W (2023) Caged polyprenylated xanthones in Garcinia hanburyi and the biological activities of them. Drug Des Devel Ther 17:3625\u20133660. https:\/\/doi.org\/10.2147\/DDDT.S426685","journal-title":"Drug Des Devel Ther"},{"key":"1590_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X (2024) Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther 9:209. https:\/\/doi.org\/10.1038\/s41392-024-01891-4","journal-title":"Signal Transduct Target Ther"},{"key":"1590_CR65","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4155\/fmc-2017-0294","volume":"10","author":"TT Ho","year":"2018","unstructured":"Ho TT, Tran QT, Chai CL (2018) The polypharmacology of natural products. Future Med Chem 10:1361\u20131368. https:\/\/doi.org\/10.4155\/fmc-2017-0294","journal-title":"Future Med Chem"},{"key":"1590_CR66","doi-asserted-by":"publisher","first-page":"9417","DOI":"10.1007\/s00210-024-03281-7","volume":"397","author":"NQ Hop","year":"2024","unstructured":"Hop NQ, Son NT (2024) The quassinoids bruceines A-M: pharmacology, mechanism of action, synthetic advance, and pharmacokinetics-a review. Naunyn Schmiedebergs Arch Pharmacol 397:9417\u20139433. https:\/\/doi.org\/10.1007\/s00210-024-03281-7","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1590_CR67","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/pros.23469","volume":"78","author":"H Huang","year":"2018","unstructured":"Huang H, Wang Q, Du T, Lin C, Lai Y, Zhu D, Wu W, Ma X, Bai S, Li Z, Liu L, Li Q (2018) Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B. Prostate 78:327\u2013335. https:\/\/doi.org\/10.1002\/pros.23469","journal-title":"Prostate"},{"key":"1590_CR68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13659-020-00293-7","volume":"11","author":"M Huang","year":"2021","unstructured":"Huang M, Lu JJ, Ding J (2021) Natural products in cancer therapy: past, present and future. Nat Prod Bioprospect 11:5\u201313. https:\/\/doi.org\/10.1007\/s13659-020-00293-7","journal-title":"Nat Prod Bioprospect"},{"key":"1590_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122849","volume":"351","author":"S Huang","year":"2024","unstructured":"Huang S, Zhang J, Wu X, Liang B, Pang N, Yang L, Zhang Z (2024) RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression. Life Sci 351:122849. https:\/\/doi.org\/10.1016\/j.lfs.2024.122849","journal-title":"Life Sci"},{"key":"1590_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s13402-025-01039-8","volume":"48","author":"Z Huang","year":"2025","unstructured":"Huang Z, Li Y, Zhao Z, Ye L, Zhang T, Yu Z, Zhai E, Qian Y, Xu X, Zhao R, Cai S, Chen J (2025) Enhanced ZBTB10 expression induced by betulinic acid inhibits gastric cancer progression by inactivating the ARRDC3\/ITGB4\/PI3K\/AKT pathway. Cell Oncol (Dordr) 48:675\u2013692. https:\/\/doi.org\/10.1007\/s13402-025-01039-8","journal-title":"Cell Oncol (Dordr)"},{"key":"1590_CR71","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/bph.70014","volume":"182","author":"AA Izzo","year":"2025","unstructured":"Izzo AA, Stefanska B (2025) Natural products and cancer: from drug discovery to prevention and therapy. Br J Pharmacol 182:2069\u20132074. https:\/\/doi.org\/10.1111\/bph.70014","journal-title":"Br J Pharmacol"},{"key":"1590_CR72","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12967-025-06743-5","volume":"23","author":"L Ji","year":"2025","unstructured":"Ji L, Xia D, Zhou Y, Hu Y, Yang Z, Yin Y, Wang J, Zhang B, Gong L, Li K, Zou J, Wang M (2025) Spatial transcriptomics and multi-omics reveal relapse and resistance mechanisms of EndMT-derived CAFs mediated by TNC and FLNC in glioblastoma. J Transl Med 23:702. https:\/\/doi.org\/10.1186\/s12967-025-06743-5","journal-title":"J Transl Med"},{"key":"1590_CR73","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41419-019-1366-y","volume":"10","author":"S Jia","year":"2019","unstructured":"Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L (2019) Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Cell Death Dis 10:142. https:\/\/doi.org\/10.1038\/s41419-019-1366-y","journal-title":"Cell Death Dis"},{"key":"1590_CR74","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-024-02040-9","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T, Fu X, Yao X, Peng Y (2024) Advances in spatial transcriptomics and its applications in cancer research. Mol Cancer 23:129. https:\/\/doi.org\/10.1186\/s12943-024-02040-9","journal-title":"Mol Cancer"},{"key":"1590_CR75","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12915-025-02302-y","volume":"23","author":"S Jin","year":"2025","unstructured":"Jin S, Long H, Huang A, Wang J, Yu X, Xu Z, Xu J (2025) Accurate prediction of synergistic drug combination using a multi-source information fusion framework. BMC Biol 23:200. https:\/\/doi.org\/10.1186\/s12915-025-02302-y","journal-title":"BMC Biol"},{"key":"1590_CR76","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M (2025) KEGG: biological systems database as a model of the real world. Nucleic Acids Res 53:D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909","journal-title":"Nucleic Acids Res"},{"key":"1590_CR77","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/1541-7786.MCR-19-1082","volume":"18","author":"I Kastrati","year":"2020","unstructured":"Kastrati I, Joosten SEP, Semina SE, Alejo LH, Brovkovych SD, Stender JD, Horlings HM, Kok M, Alarid ET, Greene GL, Linn SC, Zwart W, Frasor J (2020) The NF-kappaB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor-positive breast cancers. Mol Cancer Res 18:1018\u20131027. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-1082","journal-title":"Mol Cancer Res"},{"key":"1590_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2025.107620","author":"S Khan","year":"2025","unstructured":"Khan S, Khan MM, Ahmad U, Khan S (2025) Fisetin as a multifunctional bioactive flavonoid: a comprehensive review of its pharmacology, mechanism of action, safety profile, clinical trials, and future directions in therapeutics. Food Biosci. https:\/\/doi.org\/10.1016\/j.fbio.2025.107620","journal-title":"Food Biosci"},{"key":"1590_CR79","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3892\/ijo.2020.5025","volume":"56","author":"JH Kim","year":"2020","unstructured":"Kim JH, Ko ES, Kim D, Park SH, Kim EJ, Rho J, Seo H, Kim MJ, Yang WM, Ha IJ, Park MJ, Lee JY (2020) Cancer cell\u2011specific anticancer effects of Coptis chinensis on gefitinib\u2011resistant lung cancer cells are mediated through the suppression of Mcl\u20111 and Bcl\u20112. Int J Oncol 56:1540\u20131550. https:\/\/doi.org\/10.3892\/ijo.2020.5025","journal-title":"Int J Oncol"},{"key":"1590_CR80","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3892\/ol.2021.12616","volume":"21","author":"SM Kim","year":"2021","unstructured":"Kim SM, Rampogu S, Vetrivel P, Kulkarni AM, Ha SE, Kim HH, Lee KW, Kim GS (2021) Transcriptome analysis of sinensetin-treated liver cancer cells guided by biological network analysis. Oncol Lett 21:355. https:\/\/doi.org\/10.3892\/ol.2021.12616","journal-title":"Oncol Lett"},{"key":"1590_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12081576","author":"A Kim","year":"2023","unstructured":"Kim A, Park SM, Kim NS, Lee H (2023) Ginsenoside Rc, an active component of Panax ginseng, alleviates oxidative stress-induced muscle atrophy via improvement of mitochondrial biogenesis. Antioxidants. https:\/\/doi.org\/10.3390\/antiox12081576","journal-title":"Antioxidants"},{"key":"1590_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155057","volume":"123","author":"A Kim","year":"2024","unstructured":"Kim A, Kim YR, Park SM, Lee H, Park M, Yi JM, Cha S, Kim NS (2024a) Jakyak-gamcho-tang, a decoction of Paeoniae Radix and Glycyrrhizae Radix et Rhizoma, ameliorates dexamethasone-induced muscle atrophy and muscle dysfunction. Phytomedicine 123:155057. https:\/\/doi.org\/10.1016\/j.phymed.2023.155057","journal-title":"Phytomedicine"},{"key":"1590_CR83","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4196\/kjpp.2024.28.5.403","volume":"28","author":"D Kim","year":"2024","unstructured":"Kim D, Jeong S, Park SM (2024b) Unraveling flavivirus pathogenesis: from bulk to single-cell RNA-sequencing strategies. Korean J Physiol Pharmacol 28:403\u2013411. https:\/\/doi.org\/10.4196\/kjpp.2024.28.5.403","journal-title":"Korean J Physiol Pharmacol"},{"key":"1590_CR84","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.freeradbiomed.2025.09.022","volume":"241","author":"A Kim","year":"2025","unstructured":"Kim A, Kim YR, Jayasinghe JNC, Park M, Cha S, Park SM, Kim NS (2025a) Licochalcone B alleviates exercise-induced muscle fatigue through its antioxidant activity in experimental mice. Free Radic Biol Med 241:204\u2013219. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.09.022","journal-title":"Free Radic Biol Med"},{"key":"1590_CR85","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jgr.2024.09.002","volume":"49","author":"A Kim","year":"2025","unstructured":"Kim A, Park SM, Kim NS, Park M, Cha S (2025b) Ginsenoside Rc prevents dexamethasone-induced muscle atrophy and enhances muscle strength and motor function. J Ginseng Res 49:42\u201352. https:\/\/doi.org\/10.1016\/j.jgr.2024.09.002","journal-title":"J Ginseng Res"},{"key":"1590_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.124011","author":"S Kim","year":"2025","unstructured":"Kim S, Kim A, Tran MN, Kim S-Y, Min B-D, Kim NS, Park S-M (2025c) Ginsenoside Rc inhibits TGF-\u03b2 signaling and downregulates nucleolin to mitigate oxidative stress-induced muscle atrophy. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2025.124011","journal-title":"Life Sci"},{"key":"1590_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118129","volume":"188","author":"SY Kim","year":"2025","unstructured":"Kim SY, Yi JM, Chun J, Park M, Yeo H, Park SM, Jeong MK (2025d) Deciphering the immunomodulatory mechanisms of Bojungikki-tang via systematic transcriptomic and immune cell interaction network analysis. Biomed Pharmacother 188:118129. https:\/\/doi.org\/10.1016\/j.biopha.2025.118129","journal-title":"Biomed Pharmacother"},{"key":"1590_CR88","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H (2023) G:profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res 51:W207\u2013W212. https:\/\/doi.org\/10.1093\/nar\/gkad347","journal-title":"Nucleic Acids Res"},{"key":"1590_CR89","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12964-024-01788-3","volume":"22","author":"M Kot","year":"2024","unstructured":"Kot M, Simiczyjew A, Wadzynska J, Zietek M, Matkowski R, Nowak D (2024) Characterization of two melanoma cell lines resistant to BRAF\/MEK inhibitors (vemurafenib and cobimetinib). Cell Commun Signal 22:410. https:\/\/doi.org\/10.1186\/s12964-024-01788-3","journal-title":"Cell Commun Signal"},{"key":"1590_CR90","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65890","volume":"16","author":"K Kumada","year":"2024","unstructured":"Kumada K, Matsumoto-Miyazaki J, Okada H, Okura H, Sato Y (2024) Successful administration of Kampo medicine and acupuncture treatment to improve erythromelalgia: a case report. Cureus 16:e65890. https:\/\/doi.org\/10.7759\/cureus.65890","journal-title":"Cureus"},{"issue":"104\u2013122","key":"1590_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhayay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Janne PA (2020) Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37(104\u2013122):e12. https:\/\/doi.org\/10.1016\/j.ccell.2019.12.006","journal-title":"Cancer Cell"},{"key":"1590_CR92","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s12272-019-01176-3","volume":"42","author":"OS Kwon","year":"2019","unstructured":"Kwon OS, Kim W, Cha HJ, Lee H (2019) In silico drug repositioning: from large-scale transcriptome data to therapeutics. Arch Pharm Res 42:879\u2013889. https:\/\/doi.org\/10.1007\/s12272-019-01176-3","journal-title":"Arch Pharm Res"},{"key":"1590_CR93","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929\u20131935. https:\/\/doi.org\/10.1126\/science.1132939","journal-title":"Science"},{"key":"1590_CR94","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.celrep.2014.07.033","volume":"8","author":"S Lamba","year":"2014","unstructured":"Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A (2014) RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep 8:1475\u20131483. https:\/\/doi.org\/10.1016\/j.celrep.2014.07.033","journal-title":"Cell Rep"},{"key":"1590_CR95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J (2014) Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26:207\u2013221. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.019","journal-title":"Cancer Cell"},{"key":"1590_CR96","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5483\/BMBRep.2022.55.9.102","volume":"55","author":"M Lee","year":"2022","unstructured":"Lee M, Shin H, Park M, Kim A, Cha S, Lee H (2022) Systems pharmacology approaches in herbal medicine research: a brief review. BMB Rep 55:417\u2013428. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.9.102","journal-title":"BMB Rep"},{"key":"1590_CR97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1541-7786.MCR-21-0038","volume":"20","author":"C Leonce","year":"2022","unstructured":"Leonce C, Saintigny P, Ortiz-Cuaran S (2022) Cell-intrinsic mechanisms of drug tolerance to systemic therapies in cancer. Mol Cancer Res 20:11\u201329. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0038","journal-title":"Mol Cancer Res"},{"key":"1590_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033379","volume":"7","author":"QL Li","year":"2012","unstructured":"Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ, Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, Zhou J (2012) Activation of PI3K\/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. PLoS ONE 7:e33379. https:\/\/doi.org\/10.1371\/journal.pone.0033379","journal-title":"PLoS ONE"},{"key":"1590_CR99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/13880209.2020.1865407","volume":"59","author":"G Li","year":"2021","unstructured":"Li G, Zhang C, Liang W, Zhang Y, Shen Y, Tian X (2021) Berberine regulates the Notch1\/PTEN\/PI3K\/AKT\/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. Pharm Biol 59:21\u201330. https:\/\/doi.org\/10.1080\/13880209.2020.1865407","journal-title":"Pharm Biol"},{"key":"1590_CR100","doi-asserted-by":"publisher","first-page":"1243820","DOI":"10.3389\/fphar.2023.1243820","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Tian F, Guo J, Li X, Ma L, Jiang M, Zhao J (2023) Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms. Front Pharmacol 14:1243820. https:\/\/doi.org\/10.3389\/fphar.2023.1243820","journal-title":"Front Pharmacol"},{"key":"1590_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155503","volume":"127","author":"D Li","year":"2024","unstructured":"Li D, Wang J, Tuo Z, Yoo KH, Yu Q, Miyamoto A, Zhang C, Ye X, Wei W, Wu R, Feng D (2024) Natural products and derivatives in renal, urothelial and testicular cancers: targeting signaling pathways and therapeutic potential. Phytomedicine 127:155503. https:\/\/doi.org\/10.1016\/j.phymed.2024.155503","journal-title":"Phytomedicine"},{"key":"1590_CR102","doi-asserted-by":"publisher","first-page":"1612089","DOI":"10.3389\/fphar.2025.1612089","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, Xu W, Cheng W, Tang D (2025a) Drug-tolerant persister (DTP) cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies. Front Pharmacol 16:1612089. https:\/\/doi.org\/10.3389\/fphar.2025.1612089","journal-title":"Front Pharmacol"},{"key":"1590_CR103","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41417-025-00937-1","volume":"32","author":"S Li","year":"2025","unstructured":"Li S, Oh GH, Hong JA, Choi S, Kim M, Kwon H, Ko SK, Park SJ, Kim HK, Choi HJ, Song JJ (2025b) Combined downregulation of TGF-beta1 and GRP78 is responsible for overcoming acquired sorafenib resistance, which is initiated by rewiring the cell surface CD44-GRP78-IGF-1R signaling circuit. Cancer Gene Ther 32:884\u2013898. https:\/\/doi.org\/10.1038\/s41417-025-00937-1","journal-title":"Cancer Gene Ther"},{"key":"1590_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106849","volume":"194","author":"H Liang","year":"2023","unstructured":"Liang H, Huang Q, Zou L, Wei P, Lu J, Zhang Y (2023) Methyl gallate: review of pharmacological activity. Pharmacol Res 194:106849. https:\/\/doi.org\/10.1016\/j.phrs.2023.106849","journal-title":"Pharmacol Res"},{"key":"1590_CR105","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27:1739\u20131740. https:\/\/doi.org\/10.1093\/bioinformatics\/btr260","journal-title":"Bioinformatics"},{"key":"1590_CR106","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P (2015) The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst 1:417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004","journal-title":"Cell Syst"},{"key":"1590_CR107","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","volume":"22","author":"P Lito","year":"2012","unstructured":"Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, De Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N (2012) Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22:668\u2013682. https:\/\/doi.org\/10.1016\/j.ccr.2012.10.009","journal-title":"Cancer Cell"},{"key":"1590_CR108","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY (2024a) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther 9:175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7","journal-title":"Signal Transduct Target Ther"},{"key":"1590_CR109","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3892\/ol.2024.14315","volume":"27","author":"Y Liu","year":"2024","unstructured":"Liu Y, Li G, Ning J, Zhao Y (2024b) Unveiling the experimental proof of the anticancer potential of ginsenoside Rg3 (review). Oncol Lett 27:182. https:\/\/doi.org\/10.3892\/ol.2024.14315","journal-title":"Oncol Lett"},{"key":"1590_CR110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/jca.100922","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu H, Li Y, Karsidag M, Tu T, Wang P (2025a) Technical and biological biases in bulk transcriptomic data mining for cancer research. J Cancer 16:34\u201343. https:\/\/doi.org\/10.7150\/jca.100922","journal-title":"J Cancer"},{"key":"1590_CR111","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","volume":"24","author":"S Liu","year":"2025","unstructured":"Liu S, Jiang A, Tang F, Duan M, Li B (2025b) Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer 24:150. https:\/\/doi.org\/10.1186\/s12943-025-02323-9","journal-title":"Mol Cancer"},{"key":"1590_CR112","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.5114\/aoms\/196381","volume":"21","author":"WQ Lu","year":"2025","unstructured":"Lu WQ, Li XD, Gu Y, Huang JM, Qin YK, Cai XY, Wang CM (2025) Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90\/HIF-1alpha\/EMT axis. Arch Med Sci 21:1487\u20131501. https:\/\/doi.org\/10.5114\/aoms\/196381","journal-title":"Arch Med Sci"},{"key":"1590_CR113","first-page":"3585","volume":"36","author":"H Luo","year":"2016","unstructured":"Luo H, Umebayashi M, Doi K, Morisaki T, Shirasawa S, Tsunoda T (2016) Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of AKT in BRAF-mutated melanoma cells. Anticancer Res 36:3585\u20133589","journal-title":"Anticancer Res"},{"key":"1590_CR114","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1875-5364(24)60582-0","volume":"22","author":"Z Luo","year":"2024","unstructured":"Luo Z, Yin F, Wang X, Kong L (2024) Progress in approved drugs from natural product resources. Chin J Nat Med 22:195\u2013211. https:\/\/doi.org\/10.1016\/S1875-5364(24)60582-0","journal-title":"Chin J Nat Med"},{"key":"1590_CR115","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41419-017-0247-5","volume":"9","author":"C Lv","year":"2018","unstructured":"Lv C, Zeng HW, Wang JX, Yuan X, Zhang C, Fang T, Yang PM, Wu T, Zhou YD, Nagle DG, Zhang WD (2018) The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Cell Death Dis 9:165. https:\/\/doi.org\/10.1038\/s41419-017-0247-5","journal-title":"Cell Death Dis"},{"key":"1590_CR116","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/bib\/bbt002","volume":"15","author":"H Maciejewski","year":"2014","unstructured":"Maciejewski H (2014) Gene set analysis methods: statistical models and methodological differences. Brief Bioinform 15:504\u2013518. https:\/\/doi.org\/10.1093\/bib\/bbt002","journal-title":"Brief Bioinform"},{"key":"1590_CR117","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine JC, Dawson SJ, Dawson MA (2020) Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer 20:743\u2013756. https:\/\/doi.org\/10.1038\/s41568-020-00302-4","journal-title":"Nat Rev Cancer"},{"key":"1590_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148607","volume":"925","author":"JR Mekala","year":"2024","unstructured":"Mekala JR, Nalluri HP, Reddy PN, S BS, N SS, G VSDS, Dhiman R, Chamarthy S, Komaragiri RR, Manyam RR, Dirisala VR (2024) Emerging trends and therapeutic applications of monoclonal antibodies. Gene 925:148607. https:\/\/doi.org\/10.1016\/j.gene.2024.148607","journal-title":"Gene"},{"key":"1590_CR119","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"HY Min","year":"2022","unstructured":"Min HY, Lee HY (2022) Molecular targeted therapy for anticancer treatment. Exp Mol Med 54:1670\u20131694. https:\/\/doi.org\/10.1038\/s12276-022-00864-3","journal-title":"Exp Mol Med"},{"key":"1590_CR120","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.afos.2025.05.002","volume":"11","author":"BD Min","year":"2025","unstructured":"Min BD, Hwang CY, Kim D, Kim SY, Jayasinghe JNC, Tran MN, Park SM, Kwon KS (2025) Advancing muscle aging and sarcopenia research through spatial transcriptomics. Osteoporos Sarcopenia 11:22\u201331. https:\/\/doi.org\/10.1016\/j.afos.2025.05.002","journal-title":"Osteoporos Sarcopenia"},{"key":"1590_CR121","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","volume":"69","author":"OK Mirzoeva","year":"2009","unstructured":"Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, Mccormick F, Kuo WL, Mills GB, Gray JW, Korn WM (2009) Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69:565\u2013572. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3389","journal-title":"Cancer Res"},{"key":"1590_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040612","author":"K Miyazaki","year":"2023","unstructured":"Miyazaki K, Morine Y, Xu C, Nakasu C, Wada Y, Teraoku H, Yamada S, Saito Y, Ikemoto T, Shimada M, Goel A (2023) Curcumin-mediated resistance to lenvatinib via EGFR signaling pathway in hepatocellular carcinoma. Cells. https:\/\/doi.org\/10.3390\/cells12040612","journal-title":"Cells"},{"key":"1590_CR123","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1158\/1541-7786.MCR-18-0212","volume":"16","author":"C Mulder","year":"2018","unstructured":"Mulder C, Prust N, Van Doorn S, Reinecke M, Kuster B, Van Bergen En Henegouwen P, Lemeer S (2018) Adaptive resistance to EGFR-targeted therapy by calcium signaling in NSCLC cells. Mol Cancer Res 16:1773\u20131784. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0212","journal-title":"Mol Cancer Res"},{"key":"1590_CR124","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","volume":"21","author":"T Muranen","year":"2012","unstructured":"Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS (2012) Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21:227\u2013239. https:\/\/doi.org\/10.1016\/j.ccr.2011.12.024","journal-title":"Cancer Cell"},{"key":"1590_CR125","doi-asserted-by":"publisher","first-page":"10059","DOI":"10.1002\/fsn3.4639","volume":"12","author":"E Nemli","year":"2024","unstructured":"Nemli E, Saricaoglu B, Kirkin C, Ozkan G, Capanoglu E, Habtemariam S, Sharifi-Rad J, Calina D (2024) Chemopreventive and chemotherapeutic potential of betulin and betulinic acid: mechanistic insights from in vitro, in vivo and clinical studies. Food Sci Nutr 12:10059\u201310069. https:\/\/doi.org\/10.1002\/fsn3.4639","journal-title":"Food Sci Nutr"},{"key":"1590_CR126","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM (2020) Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod 83:770\u2013803. https:\/\/doi.org\/10.1021\/acs.jnatprod.9b01285","journal-title":"J Nat Prod"},{"key":"1590_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12071320","author":"TK Ng","year":"2023","unstructured":"Ng TK, Chu KO, Wang CC, Pang CP (2023) Green tea catechins as therapeutic antioxidants for glaucoma treatment. Antioxidants. https:\/\/doi.org\/10.3390\/antiox12071320","journal-title":"Antioxidants"},{"key":"1590_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101663","volume":"5","author":"MJ Nokin","year":"2024","unstructured":"Nokin MJ, Darbo E, Richard E, San Jose S, De Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Janne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaria D, Bolero C (2024) In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF(V600E) lung adenocarcinoma. Cell Rep Med 5:101663. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101663","journal-title":"Cell Rep Med"},{"key":"1590_CR129","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'reilly","year":"2006","unstructured":"O\u2019reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500\u20131508. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2925","journal-title":"Cancer Res"},{"key":"1590_CR130","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/febs.14773","volume":"286","author":"SM Park","year":"2019","unstructured":"Park SM, Hwang CY, Cho SH, Lee D, Gong JR, Lee S, Nam S, Cho KH, Cho KH (2019) Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. FEBS J 286:1305\u20131318. https:\/\/doi.org\/10.1111\/febs.14773","journal-title":"FEBS J"},{"key":"1590_CR131","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1038\/s41388-020-1255-y","volume":"39","author":"SM Park","year":"2020","unstructured":"Park SM, Hwang CY, Choi J, Joung CY, Cho KH (2020) Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy. Oncogene 39:3803\u20133820. https:\/\/doi.org\/10.1038\/s41388-020-1255-y","journal-title":"Oncogene"},{"key":"1590_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102673","author":"Y Park","year":"2021","unstructured":"Park Y, Jeong J, Seong S, Kim W (2021) In silico evaluation of natural compounds for an acidic extracellular environment in human breast cancer. Cells. https:\/\/doi.org\/10.3390\/cells10102673","journal-title":"Cells"},{"key":"1590_CR133","doi-asserted-by":"publisher","first-page":"1010520","DOI":"10.3389\/fphar.2022.1010520","volume":"13","author":"SM Park","year":"2022","unstructured":"Park SM, Kim A, Lee H, Baek SJ, Kim NS, Park M, Yi JM, Cha S (2022) Systematic transcriptome analysis reveals molecular mechanisms and indications of bupleuri radix. Front Pharmacol 13:1010520. https:\/\/doi.org\/10.3389\/fphar.2022.1010520","journal-title":"Front Pharmacol"},{"key":"1590_CR134","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad344","author":"M Park","year":"2023","unstructured":"Park M, Baek SJ, Park SM, Yi JM, Cha S (2023) Comparative study of the mechanism of natural compounds with similar structures using docking and transcriptome data for improving in silico herbal medicine experimentations. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbad344","journal-title":"Brief Bioinform"},{"key":"1590_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03734-x","volume":"11","author":"M Park","year":"2024","unstructured":"Park M, Park SM, Lee H, Kim A, Kim NS, Kim YR, Yi JM, Cha S (2024a) KORE-Map 1.0: Korean medicine omics resource extension map on transcriptome data of tonifying herbal medicine. Sci Data 11:974. https:\/\/doi.org\/10.1038\/s41597-024-03734-x","journal-title":"Sci Data"},{"key":"1590_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13738","author":"SM Park","year":"2024","unstructured":"Park SM, Haam K, Heo H, Kim D, Kim MJ, Jung HJ, Cha S, Kim M, Lee H (2024b) Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer. Mol Oncol. https:\/\/doi.org\/10.1002\/1878-0261.13738","journal-title":"Mol Oncol"},{"key":"1590_CR137","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jgr.2022.03.004","volume":"47","author":"MA Potenza","year":"2023","unstructured":"Potenza MA, Montagnani M, Santacroce L, Charitos IA, Bottalico L (2023) Ancient herbal therapy: a brief history of Panax ginseng. J Ginseng Res 47:359\u2013365. https:\/\/doi.org\/10.1016\/j.jgr.2022.03.004","journal-title":"J Ginseng Res"},{"key":"1590_CR138","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/acsmedchemlett.3c00015","volume":"14","author":"LL Pruteanu","year":"2023","unstructured":"Pruteanu LL, Bender A (2023) Using transcriptomics and cell morphology data in drug discovery: the long road to practice. ACS Med Chem Lett 14:386\u2013395. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00015","journal-title":"ACS Med Chem Lett"},{"key":"1590_CR139","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, Vallette F, Shen S (2023) Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol 20:799\u2013813. https:\/\/doi.org\/10.1038\/s41571-023-00815-5","journal-title":"Nat Rev Clin Oncol"},{"key":"1590_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53457-1","volume":"15","author":"X Qi","year":"2024","unstructured":"Qi X, Zhao L, Tian C, Li Y, Chen ZL, Huo P, Chen R, Liu X, Wan B, Yang S, Zhao Y (2024) Predicting transcriptional responses to novel chemical perturbations using deep generative model for drug discovery. Nat Commun 15:9256. https:\/\/doi.org\/10.1038\/s41467-024-53457-1","journal-title":"Nat Commun"},{"key":"1590_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116957","volume":"318","author":"HQ Qian","year":"2024","unstructured":"Qian HQ, Wu DC, Li CY, Liu XR, Han XK, Peng Y, Zhang H, Zhao BY, Zhao Y (2024) A systematic review of traditional uses, phytochemistry, pharmacology and toxicity of Epimedium koreanum Nakai. J Ethnopharmacol 318:116957. https:\/\/doi.org\/10.1016\/j.jep.2023.116957","journal-title":"J Ethnopharmacol"},{"key":"1590_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.09.006","author":"L Qiao","year":"2025","unstructured":"Qiao L, Huo X, Huang W, Wang Z, Ren Y, Liu Y, Li Q, Zhang Y (2025) Advances in high-throughput drug screening based on pharmacotranscriptomics. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2025.09.006","journal-title":"J Adv Res"},{"key":"1590_CR143","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12864-016-3149-5","volume":"17","author":"R Raghavan","year":"2016","unstructured":"Raghavan R, Hyter S, Pathak HB, Godwin AK, Konecny G, Wang C, Goode EL, Fridley BL (2016) Drug discovery using clinical outcome-based connectivity mapping: application to ovarian cancer. BMC Genom 17:811. https:\/\/doi.org\/10.1186\/s12864-016-3149-5","journal-title":"BMC Genom"},{"key":"1590_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30143022","volume":"30","author":"NA Raut","year":"2025","unstructured":"Raut NA, Kanabar PN, Maienschein-Cline M, Los NS, Arbieva Z, Lawal TO, Patel S, Mahady GB (2025) RNA-seq analysis of MCF-7 breast cancer cells treated with methyl gallate isolated from the rhizomes of Nymphaea odorata L. shows upregulation of apoptosis, autophagy, and unfolded protein canonical pathways. Molecules 30:3022. https:\/\/doi.org\/10.3390\/molecules30143022","journal-title":"Molecules"},{"key":"1590_CR145","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03002-x","volume":"42","author":"N Ravi","year":"2025","unstructured":"Ravi N, Tye GJ, Dhaliwal SS, Musa MY, Wong MTJ, Lai NS (2025) Immune profiling in oncology: bridging the gap between technology and treatment. Med Oncol 42:446. https:\/\/doi.org\/10.1007\/s12032-025-03002-x","journal-title":"Med Oncol"},{"key":"1590_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70252","volume":"6","author":"ZQ Ren","year":"2025","unstructured":"Ren ZQ, Zheng SY, Sun Z, Luo Y, Wang YT, Yi P, Li YS, Huang C, Xiao WF (2025) Resveratrol: molecular mechanisms, health benefits, and potential adverse effects. MedComm 6:e70252. https:\/\/doi.org\/10.1002\/mco2.70252","journal-title":"MedComm"},{"key":"1590_CR147","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/1535-7163.MCT-10-0625","volume":"9","author":"JK Rho","year":"2010","unstructured":"Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, Woo SK, Kim HR, Kim CH, Choi CM, Lee JC (2010) Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther 9:3233\u20133243. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0625","journal-title":"Mol Cancer Ther"},{"key":"1590_CR148","doi-asserted-by":"publisher","first-page":"345","DOI":"10.18632\/oncotarget.28587","volume":"15","author":"E Roca","year":"2024","unstructured":"Roca E, Colloca G, Lombardo F, Bellieni A, Cucinella A, Madonia G, Martinelli L, Damiani ME, Zampieri I, Santo A (2024) The importance of integrated therapies on cancer: silibinin, an old and new molecule. Oncotarget 15:345\u2013353. https:\/\/doi.org\/10.18632\/oncotarget.28587","journal-title":"Oncotarget"},{"key":"1590_CR149","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.csbj.2024.02.018","volume":"23","author":"D Rosati","year":"2024","unstructured":"Rosati D, Palmieri M, Brunelli G, Morrione A, Iannelli F, Frullanti E, Giordano A (2024) Differential gene expression analysis pipelines and bioinformatic tools for the identification of specific biomarkers: a review. Comput Struct Biotechnol J 23:1154\u20131168. https:\/\/doi.org\/10.1016\/j.csbj.2024.02.018","journal-title":"Comput Struct Biotechnol J"},{"key":"1590_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212402","author":"M Roszkowska","year":"2024","unstructured":"Roszkowska M (2024) Multilevel mechanisms of cancer drug resistance. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252212402","journal-title":"Int J Mol Sci"},{"key":"1590_CR151","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","volume":"19","author":"JK Rotow","year":"2024","unstructured":"Rotow JK, Lee JK, Madison RW, Oxnard GR, Janne PA, Schrock AB (2024) Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. J Thorac Oncol 19:227\u2013239. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1453","journal-title":"J Thorac Oncol"},{"key":"1590_CR152","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","volume":"13","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt E, Soares HP, Sinnet-Smith J (2014) Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther 13:2477\u20132488. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0330","journal-title":"Mol Cancer Ther"},{"key":"1590_CR153","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12964-019-0430-7","volume":"17","author":"S Saraswati","year":"2019","unstructured":"Saraswati S, Alhaider A, Abdelgadir AM, Tanwer P, Korashy HM (2019) Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt\/VEGFR2 pathway in hepatocellular carcinoma. Cell Commun Signal 17:127. https:\/\/doi.org\/10.1186\/s12964-019-0430-7","journal-title":"Cell Commun Signal"},{"key":"1590_CR154","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003","journal-title":"Sci Transl Med"},{"key":"1590_CR155","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/onc.2010.626","volume":"30","author":"V Serra","year":"2011","unstructured":"Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547\u20132557. https:\/\/doi.org\/10.1038\/onc.2010.626","journal-title":"Oncogene"},{"key":"1590_CR156","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","volume":"25","author":"KN Shah","year":"2019","unstructured":"Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, Mccormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S (2019) Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med 25:111\u2013118. https:\/\/doi.org\/10.1038\/s41591-018-0264-7","journal-title":"Nat Med"},{"key":"1590_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1136067","volume":"14","author":"X Shi","year":"2023","unstructured":"Shi X, Zhang W, Bao X, Liu X, Yang M, Yin C (2023a) Eugenol modulates the NOD1-NF-kappaB signaling pathway via targeting NF-kappaB protein in triple-negative breast cancer cells. Front Endocrinol (Lausanne) 14:1136067. https:\/\/doi.org\/10.3389\/fendo.2023.1136067","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1590_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, Wang W, Chen ZS, Han CH (2023b) Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther 8:113. https:\/\/doi.org\/10.1038\/s41392-023-01383-x","journal-title":"Signal Transduct Target Ther"},{"key":"1590_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.fbio.2024.105112","volume":"62","author":"MV Silva","year":"2024","unstructured":"Silva MV, De Lima ADCA, Silva MG, Caetano VF, De Andrade MF, Da Silva RGC, De Moraes LEPT, De Lima Silva ID, Vinhas GM (2024) Clove essential oil and eugenol: a review of their significance and uses. Food Biosci 62:105112. https:\/\/doi.org\/10.1016\/j.fbio.2024.105112","journal-title":"Food Biosci"},{"key":"1590_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.prmcm.2023.100353","volume":"10","author":"N Singh","year":"2024","unstructured":"Singh N, Agrawal P (2024) A comprehensive review on the pharmacognostic and toxicological profile of Podophyllum peltatum (Bajiaolian). Pharmacol Res Mod Chin Med 10:100353. https:\/\/doi.org\/10.1016\/j.prmcm.2023.100353","journal-title":"Pharmacol Res Mod Chin Med"},{"key":"1590_CR161","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/01635581.2014.895392","volume":"66","author":"J Song","year":"2014","unstructured":"Song J, Zhong R, Huang H, Zhang Z, Ding D, Yan H, Sun E, Jia X (2014) Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells. Nutr Cancer 66:682\u2013689. https:\/\/doi.org\/10.1080\/01635581.2014.895392","journal-title":"Nutr Cancer"},{"key":"1590_CR162","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-18-0304","volume":"24","author":"KA Song","year":"2018","unstructured":"Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle BE, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos S, Yatabe Y, Ebi H, Faber AC (2018) Increased synthesis of MCL-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target. Clin Cancer Res 24:5658\u20135672. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0304","journal-title":"Clin Cancer Res"},{"key":"1590_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.342","volume":"4","author":"X Song","year":"2023","unstructured":"Song X, Lan Y, Zheng X, Zhu Q, Liao X, Liu K, Zhang W, Peng Q, Zhu Y, Zhao L, Chen X, Shu Y, Yang K, Hu J (2023) Targeting drug-tolerant cells: a promising strategy for overcoming acquired drug resistance in cancer cells. MedComm 4:e342. https:\/\/doi.org\/10.1002\/mco2.342","journal-title":"MedComm"},{"key":"1590_CR164","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","volume":"25","author":"A Soragni","year":"2025","unstructured":"Soragni A, Knudsen ES, O\u2019connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute Acquired Resistance to Therapy, N (2025) Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer 25:613\u2013633. https:\/\/doi.org\/10.1038\/s41568-025-00824-9","journal-title":"Nat Rev Cancer"},{"key":"1590_CR165","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.189","volume":"8","author":"NM Stubbs","year":"2025","unstructured":"Stubbs NM, Roady TJ, Schwermann MP, Eteshola EO, Macdonald WJ, Purcell C, Ryspayeva D, Verovkina N, Tajiknia V, Ghandali M, Voong V, Lannigan AJ, Raufi AG, Lawler S, Holder SL, Carneiro BA, Cheng L, Safran HP, Graff SL, Dizon DS, Mani SA, Seyhan AA, Sobol RW, Wong ET, Chen CC, Gokaslan Z, Taylor MS, Rivers BM, El-Deiry WS (2025) Acquired resistance to molecularly targeted therapies for cancer. Cancer Drug Resist 8:27. https:\/\/doi.org\/10.20517\/cdr.2024.189","journal-title":"Cancer Drug Resist"},{"key":"1590_CR166","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao WN, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR (2017) A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171:1437-1452 e17. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049","journal-title":"Cell"},{"key":"1590_CR167","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","volume":"5","author":"X Sun","year":"2024","unstructured":"Sun X, Wu LF, Altschuler SJ, Hata AN (2024) Targeting therapy-persistent residual disease. Nat Cancer 5:1298\u20131304. https:\/\/doi.org\/10.1038\/s43018-024-00819-9","journal-title":"Nat Cancer"},{"key":"1590_CR168","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i8.107490","volume":"16","author":"X Sun","year":"2025","unstructured":"Sun X, Shi XW, Han L, Zhang YF, Xu Y, Lu YC (2025) Recent progress in the use of periplocin, periplocymarin and periplogenin in cancer treatment. World J Clin Oncol 16:107490. https:\/\/doi.org\/10.5306\/wjco.v16.i8.107490","journal-title":"World J Clin Oncol"},{"key":"1590_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fsysb.2023.1126044","volume":"3","author":"B Szalai","year":"2023","unstructured":"Szalai B, Veres DV (2023) Application of perturbation gene expression profiles in drug discovery-from mechanism of action to quantitative modelling. Front Syst Biol 3:1126044. https:\/\/doi.org\/10.3389\/fsysb.2023.1126044","journal-title":"Front Syst Biol"},{"key":"1590_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101353","author":"WH Talib","year":"2021","unstructured":"Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI (2021) Targeting drug chemo-resistance in cancer using natural products. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9101353","journal-title":"Biomedicines"},{"key":"1590_CR171","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.5114\/wo.2014.47136","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwinska P, Wiznerowicz M (2015) The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 19:A68-77. https:\/\/doi.org\/10.5114\/wo.2014.47136","journal-title":"Contemp Oncol (Pozn)"},{"key":"1590_CR172","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, Kegyes D, Onaciu A, Gulei D, Ghiaur G, Einsele H, Croce CM (2024) Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther 9:201. https:\/\/doi.org\/10.1038\/s41392-024-01899-w","journal-title":"Signal Transduct Target Ther"},{"key":"1590_CR173","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1039\/d1cb00069a","volume":"3","author":"MA Trapotsi","year":"2022","unstructured":"Trapotsi MA, Hosseini-Gerami L, Bender A (2022) Computational analyses of mechanism of action (MoA): data, methods and integration. RSC Chem Biol 3:170\u2013200. https:\/\/doi.org\/10.1039\/d1cb00069a","journal-title":"RSC Chem Biol"},{"key":"1590_CR174","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72:3228\u20133237. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3747","journal-title":"Cancer Res"},{"key":"1590_CR175","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41573-023-00688-4","volume":"22","author":"B Van De Sande","year":"2023","unstructured":"Van De Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, Manning J, Wang Y, Pollard J, Mendez M, Hill J, Kumar N, Cao X, Chen X, Khaladkar M, Wen J, Leach A, Ferran E (2023) Applications of single-cell RNA sequencing in drug discovery and development. Nat Rev Drug Discov 22:496\u2013520. https:\/\/doi.org\/10.1038\/s41573-023-00688-4","journal-title":"Nat Rev Drug Discov"},{"key":"1590_CR176","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1101\/gr.266213.120","volume":"31","author":"A Varabyou","year":"2020","unstructured":"Varabyou A, Salzberg SL, Pertea M (2020) Effects of transcriptional noise on estimates of gene and transcript expression in RNA sequencing experiments. Genome Res 31:301\u2013308. https:\/\/doi.org\/10.1101\/gr.266213.120","journal-title":"Genome Res"},{"key":"1590_CR177","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R (2021) Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res 81:5589\u20135595. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1606","journal-title":"Cancer Res"},{"key":"1590_CR178","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1158\/1078-0432.CCR-18-2779","volume":"25","author":"VE Wang","year":"2019","unstructured":"Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, Mccormick F (2019) Adaptive resistance to dual BRAF\/MEK inhibition in BRAF-driven tumors through autocrine FGFR pathway activation. Clin Cancer Res 25:7202\u20137217. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2779","journal-title":"Clin Cancer Res"},{"key":"1590_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216332","volume":"570","author":"W Wang","year":"2023","unstructured":"Wang W, Li M, Wang L, Chen L, Goh BC (2023) Curcumin in cancer therapy: exploring molecular mechanisms and overcoming clinical challenges. Cancer Lett 570:216332. https:\/\/doi.org\/10.1016\/j.canlet.2023.216332","journal-title":"Cancer Lett"},{"key":"1590_CR180","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.7150\/ijbs.113709","volume":"21","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xue F, Assaraf YG, Lin Y (2025a) Harnessing natural products to surmount drug resistance in gastric cancer: mechanisms and therapeutic perspectives. Int J Biol Sci 21:4604\u20134628. https:\/\/doi.org\/10.7150\/ijbs.113709","journal-title":"Int J Biol Sci"},{"key":"1590_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.phyplu.2025.100748","author":"R Wang","year":"2025","unstructured":"Wang R, Qiu L, Zhang Q-W, Lin L (2025b) Ethnopharmocology, phytochemistry and pharmacology of the genus Orthosiphon: a review. Phytomed Plus. https:\/\/doi.org\/10.1016\/j.phyplu.2025.100748","journal-title":"Phytomed Plus"},{"key":"1590_CR182","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang M, Dong B, Wang Y, Ding Z, Shen S (2025c) Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside. Nat Commun 16:10048. https:\/\/doi.org\/10.1038\/s41467-025-66376-6","journal-title":"Nat Commun"},{"key":"1590_CR183","doi-asserted-by":"publisher","first-page":"1353234","DOI":"10.3389\/fphar.2024.1353234","volume":"15","author":"S Wei","year":"2024","unstructured":"Wei S, Xiao J, Ju F, Liu J, Hu Z (2024) A review on the pharmacology, pharmacokinetics and toxicity of sophocarpine. Front Pharmacol 15:1353234. https:\/\/doi.org\/10.3389\/fphar.2024.1353234","journal-title":"Front Pharmacol"},{"key":"1590_CR184","doi-asserted-by":"publisher","first-page":"1199087","DOI":"10.3389\/fgene.2023.1199087","volume":"14","author":"JS Wekesa","year":"2023","unstructured":"Wekesa JS, Kimwele M (2023) A review of multi-omics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. Front Genet 14:1199087. https:\/\/doi.org\/10.3389\/fgene.2023.1199087","journal-title":"Front Genet"},{"key":"1590_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101176","volume":"78","author":"D Wu","year":"2025","unstructured":"Wu D, Sun Q, Tang H, Xiao H, Luo J, Ouyang L, Sun Q (2025) Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies. Drug Resist Updat 78:101176. https:\/\/doi.org\/10.1016\/j.drup.2024.101176","journal-title":"Drug Resist Updat"},{"key":"1590_CR186","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.21037\/tcr-21-227","volume":"10","author":"B Xu","year":"2021","unstructured":"Xu B, Zhu WJ, Peng YJ, Cheng SD (2021) Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the ADAMTS18 gene. Transl Cancer Res 10:3158\u20133167. https:\/\/doi.org\/10.21037\/tcr-21-227","journal-title":"Transl Cancer Res"},{"key":"1590_CR187","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27113513","author":"C Yang","year":"2022","unstructured":"Yang C, Mai Z, Liu C, Yin S, Cai Y, Xia C (2022) Natural products in preventing tumor drug resistance and related signaling pathways. Molecules. https:\/\/doi.org\/10.3390\/molecules27113513","journal-title":"Molecules"},{"key":"1590_CR188","doi-asserted-by":"publisher","first-page":"1453205","DOI":"10.3389\/fphar.2024.1453205","volume":"15","author":"G Yang","year":"2024","unstructured":"Yang G, Yang L, Xu F (2024a) Isoalantolactone: a review on its pharmacological effects. Front Pharmacol 15:1453205. https:\/\/doi.org\/10.3389\/fphar.2024.1453205","journal-title":"Front Pharmacol"},{"key":"1590_CR189","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29071424","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yuan L, Wang K, Lu D, Meng F, Xu D, Li W, Nan Y (2024b) The role and mechanism of paeoniae radix alba in tumor therapy. Molecules. https:\/\/doi.org\/10.3390\/molecules29071424","journal-title":"Molecules"},{"key":"1590_CR190","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.62347\/RKYL8675","volume":"17","author":"Y Yang","year":"2025","unstructured":"Yang Y, He J, Long F, Liu Y, Lin L, Wei H (2025) Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT\/ERK1\/2-OPN pathway. Am J Transl Res 17:4952\u20134963. https:\/\/doi.org\/10.62347\/RKYL8675","journal-title":"Am J Transl Res"},{"key":"1590_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123097","volume":"357","author":"H Yeo","year":"2024","unstructured":"Yeo H, Lee H, Park SM, Kang HN (2024) Paeoniae radix overcomes resistance to EGFR-TKIs via aurora B pathway suppression in lung adenocarcinoma. Life Sci 357:123097. https:\/\/doi.org\/10.1016\/j.lfs.2024.123097","journal-title":"Life Sci"},{"key":"1590_CR192","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3892\/ijo.2017.4140","volume":"51","author":"R Yoshida","year":"2017","unstructured":"Yoshida R, Sasaki T, Minami Y, Hibino Y, Okumura S, Sado M, Miyokawa N, Hayashi S, Kitada M, Ohsaki Y (2017) Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. Int J Oncol 51:1533\u20131540. https:\/\/doi.org\/10.3892\/ijo.2017.4140","journal-title":"Int J Oncol"},{"key":"1590_CR193","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13059-024-03401-9","volume":"25","author":"Y Yu","year":"2024","unstructured":"Yu Y, Mai Y, Zheng Y, Shi L (2024) Assessing and mitigating batch effects in large-scale omics studies. Genome Biol 25:254. https:\/\/doi.org\/10.1186\/s13059-024-03401-9","journal-title":"Genome Biol"},{"key":"1590_CR194","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910581","volume":"11","author":"MR Yun","year":"2019","unstructured":"Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC (2019) Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. EMBO Mol Med 11:e10581. https:\/\/doi.org\/10.15252\/emmm.201910581","journal-title":"EMBO Mol Med"},{"key":"1590_CR195","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.11","volume":"7","author":"H Zeng","year":"2024","unstructured":"Zeng H, Wang W, Zhang L, Lin Z (2024) HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs. Cancer Drug Resist 7:14. https:\/\/doi.org\/10.20517\/cdr.2024.11","journal-title":"Cancer Drug Resist"},{"key":"1590_CR196","doi-asserted-by":"publisher","first-page":"1282203","DOI":"10.3389\/fphar.2023.1282203","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang P, Liu W, Wang Y (2023) The mechanisms of tanshinone in the treatment of tumors. Front Pharmacol 14:1282203. https:\/\/doi.org\/10.3389\/fphar.2023.1282203","journal-title":"Front Pharmacol"},{"key":"1590_CR197","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.chmed.2024.01.005","volume":"16","author":"L Zhang","year":"2024","unstructured":"Zhang L, Wang X, Zhang J, Liu D, Bai G (2024) Ethnopharmacology, phytochemistry, pharmacology and product application of Platycodon grandiflorum: a review. Chin Herb Med 16:327\u2013343. https:\/\/doi.org\/10.1016\/j.chmed.2024.01.005","journal-title":"Chin Herb Med"},{"key":"1590_CR198","doi-asserted-by":"publisher","unstructured":"Zhang C, Zhou W, Xu H, Xu J, Li J, Liu X, Lu X, Dai J, Jiang Y, Wang W (2025a) Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1\/glycolysis\/H3K18la positive feedback loop. Oncogene 1\u201315. https:\/\/doi.org\/10.1038\/s41388-025-03318-y","DOI":"10.1038\/s41388-025-03318-y"},{"key":"1590_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70396","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yang C, Chen X, Wu L, Yuan Z, Zhang F, Qian BZ (2025b) Cancer therapy resistance from a spatial-omics perspective. Clin Transl Med 15:e70396. https:\/\/doi.org\/10.1002\/ctm2.70396","journal-title":"Clin Transl Med"},{"key":"1590_CR200","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tig.2023.01.003","volume":"39","author":"K Zhao","year":"2023","unstructured":"Zhao K, Rhee SY (2023) Interpreting omics data with pathway enrichment analysis. Trends Genet 39:308\u2013319. https:\/\/doi.org\/10.1016\/j.tig.2023.01.003","journal-title":"Trends Genet"},{"key":"1590_CR201","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2022.01.004","volume":"165","author":"K Zhao","year":"2022","unstructured":"Zhao K, Dai Q, Wu J, Wei Z, Duan Y, Chen B (2022) Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3. Eur J Cancer 165:58\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.004","journal-title":"Eur J Cancer"},{"key":"1590_CR202","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/med.21963","volume":"43","author":"W Zhao","year":"2023","unstructured":"Zhao W, Zheng XD, Tang PY, Li HM, Liu X, Zhong JJ, Tang YJ (2023a) Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi-active components combination. Med Res Rev 43:1778\u20131808. https:\/\/doi.org\/10.1002\/med.21963","journal-title":"Med Res Rev"},{"key":"1590_CR203","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad142","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen X, Chen J, Qi X (2023b) Decoding connectivity map-based drug repurposing for oncotherapy. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbad142","journal-title":"Brief Bioinform"},{"key":"1590_CR204","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202401798","volume":"22","author":"J Zhao","year":"2025","unstructured":"Zhao J, Zhu K, Li N, Xing L, Sheng R, Shen Y, Guo R (2025) Synthetic and pharmacological activities of alantolactone and its derivatives. Chem Biodivers 22:e202401798. https:\/\/doi.org\/10.1002\/cbdv.202401798","journal-title":"Chem Biodivers"},{"key":"1590_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6:201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w","journal-title":"Signal Transduct Target Ther"},{"key":"1590_CR206","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1002\/ptr.7990","volume":"37","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Huang S, Guo Y, Ran M, Shan W, Chen WH, Tam KY (2023) Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK\/AKT\/MAPK axis. Phytother Res 37:5837\u20135853. https:\/\/doi.org\/10.1002\/ptr.7990","journal-title":"Phytother Res"},{"key":"1590_CR207","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.7150\/thno.89805","volume":"14","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Fang S, Fan B, Xu K, Xu L, Wang L, Zhu L, Chen C, Wu R, Ni J, Wang J (2024) Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer. Theranostics 14:1683\u20131700. https:\/\/doi.org\/10.7150\/thno.89805","journal-title":"Theranostics"},{"key":"1590_CR208","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molcel.2013.01.037","volume":"50","author":"K Zmajkovicova","year":"2013","unstructured":"Zmajkovicova K, Jesenberger V, Catalanotti F, Baumgartner C, Reyes G, Baccarini M (2013) MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance. Mol Cell 50:43\u201355. https:\/\/doi.org\/10.1016\/j.molcel.2013.01.037","journal-title":"Mol Cell"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01590-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01590-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01590-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:14:47Z","timestamp":1771305287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01590-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":208,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1590"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01590-w","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}